These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 25645831)

  • 1. Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels.
    Gautier-Veyret E; Fonrose X; Tonini J; Thiebaut-Bertrand A; Bartoli M; Quesada JL; Bulabois CE; Cahn JY; Stanke-Labesque F
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2305-14. PubMed ID: 25645831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
    Yasu T; Konuma T; Kato S; Kurokawa Y; Takahashi S; Tojo A
    Ann Hematol; 2016 Oct; 95(11):1845-51. PubMed ID: 27535751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of voriconazole therapy for treatment of invasive aspergillosis: Pharmacogenomics and inflammatory status need to be evaluated.
    Gautier-Veyret E; Thiebaut-Bertrand A; Roustit M; Bolcato L; Depeisses J; Schacherer M; Schummer G; Fonrose X; Stanke-Labesque F
    Br J Clin Pharmacol; 2021 Jun; 87(6):2534-2541. PubMed ID: 33217017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers.
    Cojutti P; Candoni A; Forghieri F; Isola M; Zannier ME; Bigliardi S; Luppi M; Fanin R; Pea F
    Basic Clin Pharmacol Toxicol; 2016 Jun; 118(6):474-9. PubMed ID: 26572687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.
    Li ZW; Peng FH; Yan M; Liang W; Liu XL; Wu YQ; Lin XB; Tan SL; Wang F; Xu P; Fang PF; Liu YP; Xiang DX; Zhang BK
    Ther Drug Monit; 2017 Aug; 39(4):422-428. PubMed ID: 28604474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactive Effects of Glucocorticoids and Cytochrome P450 Polymorphisms on the Plasma Trough Concentrations of Voriconazole.
    Jia SJ; Gao KQ; Huang PH; Guo R; Zuo XC; Xia Q; Hu SY; Yu Z; Xie YL
    Front Pharmacol; 2021; 12():666296. PubMed ID: 34113252
    [No Abstract]   [Full Text] [Related]  

  • 7. Inflammation is a potential risk factor of voriconazole overdose in hematological patients.
    Gautier-Veyret E; Truffot A; Bailly S; Fonrose X; Thiebaut-Bertrand A; Tonini J; Cahn JY; Stanke-Labesque F
    Fundam Clin Pharmacol; 2019 Apr; 33(2):232-238. PubMed ID: 30306637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients.
    Hu L; Huang Q; Huang S; Feng Z
    Eur J Clin Pharmacol; 2023 Sep; 79(9):1271-1278. PubMed ID: 37458772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment by Posaconazole Tablets, Compared to Posaconazole Suspension, Does Not Reduce Variability of Posaconazole Trough Concentrations.
    Gautier-Veyret E; Bolcato L; Roustit M; Weiss S; Tonini J; Brenier-Pinchart MP; Cornet M; Thiebaut-Bertrand A; Stanke-Labesque F
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Influence of Proinflammatory Cytokines on Voriconazole Trough Concentration in Patients With Different Forms of Hematologic Disorders.
    Mafuru M; Wu S; He S; Lu X; Huang J; Jiang H
    J Clin Pharmacol; 2019 Oct; 59(10):1340-1350. PubMed ID: 30997931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive Value of FMO3 Variants on Plasma Disposition and Adverse Reactions of Oral Voriconazole in Febrile Neutropenia.
    Wang X; Zhao J; Wen T; Liao X; Luo B
    Pharmacology; 2021; 106(3-4):202-210. PubMed ID: 32998136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of CYP2C19 Phenotype and Drug-Drug Interactions on Voriconazole Concentration in Pediatric Patients.
    Tian X; Zhang C; Qin Z; Wang D; Yang J; Zhang X
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0020721. PubMed ID: 34152823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients.
    Chayakulkeeree M; Poovipirom N; Siengwattana P; Maneerattanaporn M
    J Med Assoc Thai; 2015 Mar; 98(3):232-7. PubMed ID: 25920292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of voriconazole and the role of CYP2C19 genotype on treatment optimization in pediatric patients.
    Hu L; Huang S; Huang Q; Huang J; Feng Z; He G
    PLoS One; 2023; 18(9):e0288794. PubMed ID: 37695751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics may influence the impact of inflammation on voriconazole trough concentrations.
    Gautier-Veyret E; Bailly S; Fonrose X; Tonini J; Chevalier S; Thiebaut-Bertrand A; Stanke-Labesque F
    Pharmacogenomics; 2017 Aug; 18(12):1119-1123. PubMed ID: 28745547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Drug Monitoring of Voriconazole in Children from a Tertiary Care Center in China.
    Hu L; Dai TT; Zou L; Li TM; Ding XS; Yin T
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30150475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo.
    Yan M; Wu ZF; Tang D; Wang F; Xiao YW; Xu P; Zhang BK; Liu YP; Xiang DX; Banh HL
    Biomed Pharmacother; 2018 Dec; 108():60-64. PubMed ID: 30216801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels.
    Guinea J; Escribano P; Marcos-Zambrano LJ; Peláez T; Kestler M; Muñoz P; Vena A; López-Fabal F; Bouza E
    Med Mycol; 2016 May; 54(4):353-60. PubMed ID: 26739190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision?
    Zhong X; Tong X; Ju Y; Du X; Li Y
    Curr Drug Metab; 2018; 19(14):1152-1158. PubMed ID: 29361899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes.
    Shao B; Ma Y; Li Q; Wang Y; Zhu Z; Zhao H; Sun J; Dong L; Zhu Y; Zhao N; Qin Y
    Xenobiotica; 2017 Dec; 47(12):1121-1129. PubMed ID: 27937048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.